Lovastatin
Altoprev, Lovastatin (lovastatin) is a small molecule pharmaceutical. Lovastatin was first approved as Mevacor on 1987-08-31. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. The pharmaceutical is active against 3-hydroxy-3-methylglutaryl-Coenzyme A reductase. In addition, it is known to target nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Altoprev, Lovastatin (discontinued: Altoprev, Lovastatin, Mevacor)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lovastatin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALTOPREV | Covis Pharma | N-021316 RX | 2002-06-26 | 3 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| advicor | New Drug Application | 2012-10-04 |
| altoprev | New Drug Application | 2024-03-14 |
| lovastatin | ANDA | 2024-10-15 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AA: Hmg coa reductase inhibitors, plain lipid modifying drugs
— C10AA02: Lovastatin
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA01: Lovastatin and nicotinic acid
HCPCS
No data
Clinical
Clinical Trials
91 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | 3 | 5 | 2 | 11 | 21 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 2 | 4 | 1 | 2 | 9 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | 3 | 1 | 7 |
| Syndrome | D013577 | — | — | — | 4 | — | 1 | 1 | 6 |
| Coronary disease | D003327 | — | — | — | 1 | 2 | 1 | 1 | 5 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 2 | 1 | 1 | 5 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 2 | 2 | 1 | 1 | 5 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | — | — | 2 | 3 | 5 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | 2 | 1 | 1 | 4 |
| Fragile x syndrome | D005600 | — | Q99.2 | 1 | 1 | — | 1 | — | 3 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | 2 | — | 1 | 5 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | 2 | — | — | 3 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | — | 3 | — | — | 3 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | 1 | 1 | — | — | 2 |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | — | 2 | — | — | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 2 | — | — | 2 |
| Intermittent claudication | D007383 | EFO_0003876 | I73.9 | — | — | 2 | — | — | 2 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | 2 | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | 1 | — | — | 2 |
| Homozygous familial hypercholesterolemia | D000090542 | — | — | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neurofibromatosis 1 | D009456 | — | Q85.01 | 1 | 2 | — | — | 1 | 4 |
| Neurofibromatoses | D017253 | — | Q85.00 | 1 | 2 | — | — | 1 | 4 |
| Neurofibroma | D009455 | EFO_0000622 | — | 1 | 2 | — | — | 1 | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 2 |
| Melanoma | D008545 | — | — | — | 2 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | 1 | 2 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | 1 | — | — | — | 1 |
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | — | 1 | — | — | — | 1 |
Show 45 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 1 | — | — | — | 1 | 2 |
| Porokeratosis | D017499 | — | L56.5 | 1 | — | — | — | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | — | — | 1 |
| Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 2 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | — | — | — | 1 | 1 |
| Anaplastic thyroid carcinoma | D065646 | — | — | — | — | — | — | 1 | 1 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | — | — | — | 1 | 1 |
| Follicular adenocarcinoma | D018263 | — | — | — | — | — | — | 1 | 1 |
| Heart disease risk factors | D000082742 | — | — | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Diabetes insipidus | D003919 | — | E23.2 | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lovastatin |
| INN | lovastatin |
| Description | Lovastatin is a fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom). It has a role as an Aspergillus metabolite, a prodrug, an anticholesteremic drug and an antineoplastic agent. It is a polyketide, a statin (naturally occurring), a member of hexahydronaphthalenes, a delta-lactone and a fatty acid ester. It is functionally related to a (S)-2-methylbutyric acid and a mevastatin. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21 |
Identifiers
| PDB | — |
| CAS-ID | 75330-75-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL503 |
| ChEBI ID | 40303 |
| PubChem CID | 53232 |
| DrugBank | DB00227 |
| UNII ID | 9LHU78OQFD (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ITGAL
ITGAL
Organism
Homo sapiens
Gene name
ITGAL
Gene synonyms
CD11A
NCBI Gene ID
Protein name
integrin alpha-L
Protein synonyms
antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide, CD11 antigen-like family member A, CD11a, integrin gene promoter, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide), Leukocyte adhesion glycoprotein LFA-1 alpha chain, Leukocyte function-associated molecule 1 alpha chain, LFA-1 alpha, LFA-1A, lymphocyte function-associated antigen 1, alpha polypeptide
Uniprot ID
Mouse ortholog
Itgal (16408)
integrin alpha-L (Q3U159)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Lovastatin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Lovastatin
+
Niacin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,811 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,747 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use